ioGlutamatergic Neurons MAPT P301S heterozygous - Human iPSC derived cells

Wild type ioGlutamatergic Neurons (ab303447) form the genetically matched control for the ioGlutamatergic Neurons MAPT P301S heterozygous disease model. This physiologically-relevant isogenic pairing offers a rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).

ioGlutamatergic Neurons MAPT P301S heterozygous are ioGlutamatergic Neurons carrying a genetically engineered P301S mutation in the MAPT gene, encoding the tau protein. ioGlutamatergic Neurons MAPT P301S heterozygous have been reprogrammed from human iPSCs using opti-ox^TM technology, a precise reprogramming technology.

Human stem cells, within days, convert consistently into mature, functional glutamatergic neurons providing a high-quality human model for the study of FTD.

ioGlutamatergic Neurons MAPT P301S heterozygous express pan-neuronal and glutamatergic markers TUBB3, MAP2 and VGLUT2 by day 11.

This disease model offers a fast and easy-to-use system for investigations into the impact of gene function on disease progression against an isogenic control.

A homozygous disease model is also available (ab307783).

In partnership with bit.bio

Karyotype: Normal

Seeding Density: 30,000 cells/cm²

Seeding compatibility: 6-, 12-, 24-, 48-, 96- and 384-well compatible

Quality control: ICC and gene expression analysis

Research applications: Academic research, Drug development, Neurotoxicology, Genetic screening (e.g. CRISPR screening).

This product is subject to limited use licenses from iPS Academia Japan Inc, TET Systems GmbH, ERS Genomics Limited and Sigma-Aldrich Co. LLC and is developed with Bit Bio patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.